Natera names Signatera to TIME’s 2026 list; stock pre-market at EUR 361.65
Published on 10/16/2026 at 07:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCompany dates and outlook
- Natera’s related-news listing is dated October 15, 2026.
- Natera stock trades pre-market at EUR 361.65 at 7:46 a.m. CEST at Lang & Schwarz on October 16, 2026.
- The colorectal-cancer collaboration release is dated October 13, 2026 and concerns a Phase 2a trial.
Natera’s Signatera test was named to TIME’s Best Inventions of 2026 list, according to a related-news item dated October 15, 2026 on the company’s website. Separately, Natera stock was at EUR 361.65 pre-market at Lang & Schwarz at 7:46 a.m. CEST on October 16, 2026.
Pre-market price
The Lang & Schwarz price was EUR 361.65 at 7:46 a.m. CEST on October 16, 2026. The bid was EUR 358.80 and the ask was EUR 364.50. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Natera stock.
What matters today
The related-news listing on Natera’s website is dated October 15, 2026. Natera’s collaboration announcement is dated October 13, 2026 and concerns a Phase 2a colorectal-cancer trial. The study uses Signatera to identify molecular residual disease-positive patients for enrollment.
Natera said on October 13, 2026 that it was collaborating with TransCode Therapeutics on enrollment for the company’s Phase 2a trial of TTX-MC138 in colorectal cancer. Patients are eligible if they have completed curative-intent therapy and remain positive for molecular residual disease detected by Signatera, without radiographic evidence of disease. Natera said the collaboration is intended to help identify eligible patients and support trial enrollment.
Market context: Market report S&P 500.
